enVVeno Medical Posts $6.29 Q3 Loss Per Share, Targets Year-End Enrollment

enVVeno Medical posted a $4.4 million third-quarter loss and expects to begin TAVVE study enrollment before year-end, advancing clinical testing of its investigational replacement venous valve. The net loss was $4.4 million, or $6.29 per basic and diluted share, for the quarter ended Sept. 30. In the same quarter a year earlier, the company had a $4.5 million loss, or $7.89 per share. Operating expenses totaled $4.5 million, down from $4.9 million.

Source: TokenPost